Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 5/2007

01.05.2007 | Review Article

Atypical Antipsychotics for the Treatment of Bipolar Disorder

More Shadows than Lights

verfasst von: Dr Salvatore Gentile

Erschienen in: CNS Drugs | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

Atypical antipsychotics are utilised more frequently for the treatment of bipolar disorder than first-generation antipsychotics because of their improved neurological tolerability. Furthermore, recent studies suggest that psychiatric outcomes are improved in patients treated with atypical agents. The aim of this article is to review the studies evaluating the effectiveness of atypical antipsychotics in treating acute bipolar episodes (bipolar mania, bipolar depression and mixed episodes), as well as those investigating the effectiveness of atypical antipsychotics as maintenance treatment for the disorder.
Because of several relevant methodological limitations affecting the vast majority of clinical trials, evidence-based information about the effectiveness of atypical antipsychotics in treating bipolar disorder is somewhat discouraging. Moreover, data indicating effectiveness in managing the acute manic phase and in long-term maintenance treatment are quantitatively robust only for olanzapine. However, olanzapine seems to have no advantages in terms of tolerability and therapy compliance when compared with classical mood stabilisers or first-generation antipsychotics. In addition, only a few studies have investigated the efficacy of atypical antipsychotics for treating bipolar depression. Hence, information regarding the effectiveness of such medications in treating this specific phase of bipolar disorder should be considered as still preliminary.
Given this situation, further independent and well-designed studies are urgently needed before definitive conclusions on the effectiveness of most atypical antipsychotics in the different clinical situations characterising the natural course of bipolar disorder can be drawn.
Literatur
1.
World Health Organization. World health report. Mental health: new understanding, new hope. Geneva: World Health Organization, 2001
2.
Swann A. Practical management of depressive and manic episodes. In: Garza-Trevino ES, ed. Medical psychiatry: theory and practice. Vol. 1. Teaneck (NJ). World Scientific, 1989
3.
Harma BJ, Nasrallah HA, Clancy J, et al. Psychiatric diagnosis and risk for tardive dyskinesia. Arch Gen Psychiatry 1993; 40: 346–7
4.
Cavazzoni P, Berg PH, Kryhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry 2006; 67: 107–13PubMedCrossRef
5.
Dardennes R, Even C, Bange F, et al. Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders: a meta-analysis. Br J Psychiatry 1995; 166: 375–81CrossRef
6.
7.
8.
Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind, placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79–88PubMedCrossRef
9.
Swann AC, Secunda SK, Katz MM, et al. Lithium treatment of mania: clinical characteristics, specificity of symptom change, and outcome. Psychiatr Res 1986; 118: 127–41CrossRef
10.
Ahlfors UG, Baastrup PC, Dencker SJ, et al. Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981; 64: 226–37PubMedCrossRef
11.
Esparon J, Kolloori J, Naylor GJ, et al. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148: 723–5PubMedCrossRef
12.
Judd L, Akiskal H, Schletter P, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530–7PubMedCrossRef
13.
Zarate Jr CA. Antipsychotic drug side effect issues in bipolar manic patients. J Clin Psychiatry 2000; 61Suppl. 8: 52–61PubMed
14.
Miller DS, Latham LN, Lam RW. Comparative efficacy of typical and atypical antipsychotics as add-on therapy to mood stabilizers in the treatment of acute mania. J Clin Psychiatry 2001; 62(12): 975–80PubMedCrossRef
15.
Gentile S. Long-term atypical antipsychotic treatment and risk of weight gain: a literature analysis. Drug Saf 2006; 29(4): 303–19PubMedCrossRef
16.
Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res 2004; 71: 195–212PubMedCrossRef
17.
Chue P, Kovacs CS. Safety and tolerability of atypical antipsychotics in patients with bipolar disorder: prevalence, monitoring, and management. Bipol Disord 2003; 5Suppl. 2: 62–79CrossRef
18.
Gentile S. Antipsychotic-associated weight gain [letter]. Ann Pharmacother 2004; 38: 903PubMed
19.
Guille C, Sachs G, Ghaemi S. A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2000; 61: 638–42PubMedCrossRef
20.
Liebermann JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005; 353(12): 1209–23CrossRef
21.
Zyprexa (olanzapine) tablets and Zyprexa Zydis (olanzapine) orally disintegrating tablets (prescribing information). Indianapolis (IN): Eli Lilly and Company, 2004
22.
Abilify (aripiprazole) tablets and oral solution (prescribing information). Princeton (NJ): Bristol-Myers Squibb Company, 2005; Rockville (MD): Otsuka America Pharmaceutical, Inc., 2005
23.
Department of Health and Human Services, Public Health Service, Food and Drug Administration. Supplemental new drug (Seroquel®) application. Rockville (MD): Department of Health and Human Services, 2006 Oct 20
24.
Padala PR, Wengel SP, Petty F. Manic episode during treatment with aripiprazole [letter]. Am J Psychiatry 2007; 164(1): 172–3PubMedCrossRef
25.
Keck Jr PE, Marcus R, Tourkodimitris S, et al. A placebocontrolled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 1651–8PubMedCrossRef
26.
Keck Jr PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006; 67: 626–37PubMedCrossRef
27.
Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole in acute bipolar mania. Br J Psychiatry 2005; 187: 235–42PubMedCrossRef
28.
Lykouras L, Gournellis R, Angelopoulos E. Manic symptoms induced by olanzapine. Eur Neuropsychopharmacol 2001; 11(2): 97–8PubMedCrossRef
29.
Benazzi F. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder. Eur Psychiatry 1999; 14(7): 410–1PubMedCrossRef
30.
Simon AE, Aubry JM, Malky L, et al. Hypomania-like syndrome induced by olanzapine. Int Clin Psychopharmacol 1999; 14(6): 377–8PubMedCrossRef
31.
Fitz-Gerald MJ, Pinkofsky HB, Brannon G, et al. Olanzapineinduced mania [letter]. Am J Psychiatry 1999; 156: 1114PubMed
32.
Pozo P, Alcantara AG. Mania-like syndrome in a patient with chronic schizophrenia during olanzapine treatment. J Psychiatry Neurosci 1988; 23(5): 309–10
33.
Reeves RR, McBride WA, Brannon GE. Olanzapine-induced mania. J Am Osteopath Assoc 1998; 98(10): 549–50PubMed
34.
Lyndenmayer JP, Klebanov R. Olanzapine-induced manic-like syndrome. J Clin Psychiatry 1998; 59(6): 318–9CrossRef
35.
London JA. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998; 37(2): 135–6PubMedCrossRef
36.
Henry C, Demoted-Mainard J. Olanzapine-induced mania in bipolar disorder [letter]. Rev Psychiatr Neurosci 2002; 27(3): 200
37.
Fahy S, Fahy T. Induction of manic symptoms by novel antipsychotics [letter]. Br J Psychiatry 2000; 176: 597CrossRef
38.
Narayan G, Puranik A. Olanzapine-induced mania. Int J Psychiatry Clin Pract 2000; 4: 333–4CrossRef
39.
Tohen M, Ranger TM, McElroy SL, et al. Olanzapine versus placebo in treatment of acute mania. Am J Psychiatry 1999; 156: 702–9PubMed
40.
Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania. Arch Gen Psychiatry 2000; 57: 841–9PubMedCrossRef
41.
Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247–56PubMedCrossRef
42.
Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88PubMedCrossRef
43.
Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar I and type II major depression: lack of manic induction. J Affect Dis 2005; 87: 121–30PubMedCrossRef
44.
Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int J Clin Psychopharmacol 1999; 14: 339–43CrossRef
45.
Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002; 159: 1011–7PubMedCrossRef
46.
Tohen M, Chengappa KNR, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to lithium monotherapy. Arch Gen Psychiatry 2002; 59: 62–9PubMedCrossRef
47.
Tohen M, Chengappa KNR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilisers v. mood stabiliser alone. Br J Psychiatry 2004; 184: 337–45PubMedCrossRef
48.
Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002; 63: 1148–55PubMedCrossRef
49.
Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006; 67: 1025–33PubMedCrossRef
50.
Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003; 160: 1263–71PubMedCrossRef
51.
Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 1281–9PubMedCrossRef
52.
Tohen M, Goldberg JF, Gonzales-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218–26PubMedCrossRef
53.
Calabrese JR, Keck PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60PubMedCrossRef
54.
Thase ME, MacFadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol 2006; 26(6): 600–9PubMedCrossRef
55.
Delbello MP, Schwiers ML, Rosemberg HL, et al. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry 2002; 41(10): 1216–23PubMedCrossRef
56.
Yatham LN, Paulsson B, Mullen J, et al. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol 2004; 24(6): 599–606PubMedCrossRef
57.
Sachs G, Chengappa KNR, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipol Disord 2004; 6: 213–33CrossRef
58.
Mclntyre RM, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12 week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005; 15(5): 573–85CrossRef
59.
Bowden CL, Grunze H, Mullen J, et al. A randomised, double-blind, placebo-controlled efficacy of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005; 66(1): 111–21PubMedCrossRef
60.
Delbello MP, Kowatch RA, Adler CM, et al. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006; 45(3): 1–9CrossRef
61.
Atmaca M, Kuloglu M, Buyukbayram A, et al. Quetiapine-associated and dose-related hypomania in a woman with schizophrenia. Eur Psychiatry 2002; 17(5): 292–3PubMedCrossRef
62.
Benazzi F. Quetiapine-associated hypomania in a woman with schizoaffective disorder. Can J Psychiatry 2001; 46(2): 182–3PubMed
63.
Pacchiarotti I, Manfredi G, Kotzalidis GD, et al. Quetiapine-induced mania [letter]. Aust N Z J Psychiatry 2003; 37(5): 626PubMed
64.
Lykouras L, Oulis P, Hatzimanolis J. Manic symptoms associated with quetiapine treatment. Eur Neuropsychopharmacol 2003; 13: 135–6PubMedCrossRef
65.
Biancosino B, Marmai L, Facchi A, et al. Quetiapine may induce mania: a case report. Can J Psychiatry 2003; 48: 349–50PubMed
66.
Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania. Br J Psychiatry 2005; 187: 229–34PubMedCrossRef
67.
Hirschfeld RMA, Keck Jr PE, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004; 161: 1057–65PubMedCrossRef
68.
Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropsychopharmacol 1988; 21(3): 176–80
69.
Sachs GS, Grossman F, Ghaemi SN, et al. Combination of mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002; 159: 1146–54PubMedCrossRef
70.
Yatham LN, Grossman F, Augustyns I, et al. Mood stabilizers plus risperidone or placebo in the treatment of acute mania. Br J Psychiatry 2003; 182: 141–7PubMedCrossRef
71.
Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsy-chopharmacol 2005; 15: 75–84CrossRef
72.
Mithat B, Alpaslan T, Bulent C, et al. Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium: a case report. Pharmacopsychiatry 2005; 38: 105–6PubMedCrossRef
73.
Guzelcan Y, de Haan L, Scholte WF. Risperidone may induce mania. Psychopharmacology (Berl) 2002; 126(1): 85–6
74.
75.
Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related? J Clin Psychiatry 1998; 59(2): 85–6PubMedCrossRef
76.
Barkin JS, Pais Jr VM, Gaffney MF. Induction of mania by risperidone resistant to mood stabilizers. J Clin Psychopharmacol 1997; 17(1): 57–8PubMedCrossRef
77.
Schnierow BJ, Graeber DA. Manic symptoms associated with initiation of risperidone. Am J Psychiatry 1996; 153(9): 1096–7
78.
Tomlison WC. Risperidone and mania. Am J Psychiatry 1996; 153(1): 132–3
79.
O’Croinin F, Zibin T, Holt L. Hypomania associated with risperidone [letter]. Can J Psychiatry 1995; 40(1): 51PubMed
80.
Gopal S, Steffens DC, Kramer ML, et al. Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005; 66(8): 1016–20PubMedCrossRef
81.
Sundarajan V, Jainer AK. A mood stabilizer with risperidone or haloperidol for mania [letter]. Am J Psychiatry 2004; 161: 2139–40CrossRef
82.
Lu BY, Lundgren R, Escalona PR, et al. A case of ziprasidone-induced mania and the role of 5-HT2A in mood changes induced by atypical antipsychotics. J Clin Psychiatry 2002; 63(12): 1185–6PubMedCrossRef
83.
Davis R, Risch SC. Ziprasidone induction of hypomania in depression? Am J Psychiatry 2002; 195(4): 673–4CrossRef
84.
Nolan BP, Schulte Jr JJ. Mania associated with initiation of ziprasidone [letter]. J Clin Psychiatry 2003; 64(3): 336PubMedCrossRef
85.
Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: a case series and review of the mechanism. Bipol Disord 2003; 5: 72–5CrossRef
86.
Larson MF, Hauser A. Possible ziprasidone-induced mania. J Am Acad Child Adolesc Psychiatry 2003; 42: 1012–3PubMedCrossRef
87.
Privitera MR, Maharaj K. Mania from dose-related augmentation of an SSRIs. J Clin Psychiatry 2003; 64: 1393–4PubMedCrossRef
88.
Brieger P. Hypomanic episodes after receiving ziprasidone: an unintended “on-off-on” course of treatment [letter]. J Clin Psychiatry 2004; 65(1): 132PubMedCrossRef
89.
Keating AM, Aoun SL, Dean CE. Ziprasidone-associated mania. Clin Neuropharmacol 2005; 28(2): 83–6PubMedCrossRef
90.
Keck Jr PE, Versiani M, Potkin S, et al. Ziprasidone in the treatment of bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry 2003; 160: 741–8PubMedCrossRef
91.
Potkin SG, Keck Jr PE, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebocontrolled replication trial. J Clin Psychopharmacol 2005; 25(4): 301–10PubMedCrossRef
92.
93.
Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289(4): 454–65PubMedCrossRef
94.
Boyd EA, Cho MK, Bero LA. Financial conflict-of-interest policies in clinical research: issues for clinical investigators. Acad Med 2003; 78(8): 769–74PubMedCrossRef
95.
Jagadheesan K, Muirhead D. Aripiprazole for acute bipolar mania. Am J Psychiatry 2004; 161(10): 1926–7PubMedCrossRef
96.
Cipriani A, Rendell J, Geddes J. Haloperidol alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 3: CD004362PubMed
97.
Logue DD, Gonzalez N, Heligman SD, et al. Hyperglycemia in a 7-year-old child treated with aripiprazole. Am J Psychiatry 2007; 164(1): 173PubMedCrossRef
98.
99.
Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006; 163: 210–6PubMedCrossRef
100.
Gentile S. Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. J Clin Psychopharmacol 2007; 27(1): 35–45PubMedCrossRef
101.
Yatham LM, Kennedy SH. Canadian Network for Mood and Anxiety Treatment (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipol Disord 2005; 7Suppl. 3: 5–69CrossRef
102.
Saeedi H, Remington G, Christensen BK. Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 2006; 85(1–3): 222–31PubMedCrossRef
103.
McCue R, Waheed R, Urcuyo L, et al. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry 2006; 189: 443–0
104.
López-Mu>noz A, Vieta E, Rubio G, et al. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Dis 2006; 92: 161–70CrossRef
105.
Rendell JM, Gijsman HJ, Keck P, et al. Olanzapine alone or in combination for acute mania. Cochrane Database Syst Rev 2003; (3): CD004040
106.
Rendell JM, Gijsman HJ, Keck P, et al. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; (1): CD004043
107.
Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry 2006; 67(4): 509–16PubMedCrossRef
108.
Gianfrancesco FD, Rajagopalan K, Sajatovic M, et al. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics. J Clin Psychiatry 2006; 67(2): 222–32PubMedCrossRef
109.
Sajatovic M, Valenstein M, Blow FC, et al. Treatment adherence with antipsychotic medications in bipolar disorder. Bipol Disord 2006; 8: 232–41CrossRef
110.
Kusumakar V, Yatham L, Haslam D, et al. Treatment of mania, mixed states, and rapid cycling. Can J Psychiatry 1997; 42Suppl. 2: S79–86
111.
Bowden C, Brugger A, Swann A, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994; 271: 918–24PubMedCrossRef
112.
Rachid F, Bertschy G, Bondolfi G, et al. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. J Clin Psychiatry 2004; 65(11): 1537–45PubMedCrossRef
113.
Kahn DA, Sachs GS, Printz DJ, et al. Medication treatment of bipolar disorder 2000: a summary of the expert consensus guidelines. J Psychiatr Pract 2000; 6: 197–211PubMedCrossRef
114.
Olanzapine: prevention of bipolar disorder: unconvincing trials. Prescrire Int 2005; 14(78): 140–2
115.
Patel NC, Crismon ML, Pondrom M. Rehospitalization rates of patients with bipolar disorder discharged on a mood stabilizer versus a mood stabilizer plus an atypical or typical antipsychotic. J Behav Health Serv Res 2005; 32(4): 438–45PubMedCrossRef
116.
Ehret MJ, Levin GM. Long-term use of atypical antipsychotics in bipolar disorder. Pharmacother 2006; 26(8): 1134–47CrossRef
117.
Muzina DJ, Calabrese JR. Maintenance therapies in bipolar disorder: focus on randomized controlled trials. A N Z J Psychiatry 2005; 39: 652–61CrossRef
118.
Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003; 17: 149–73PubMedCrossRef
119.
American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2004; 159: 1–50
120.
Coppen A, Farmer R. Suicide mortality in patients on lithium maintenance therapy. J Affect Disord 1998; 50: 261–7PubMedCrossRef
121.
Sachs G, Bowden C, Calabrese JR, et al. Effects of lamotrigine and lithium on body weight during maintenance treatment of bipolar I disorder. Bipolar Disord 2006; 8(2): 175–81PubMedCrossRef
122.
Suppes T, Dennehy EB, Hirschfield RM, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder. J Clin Psychiatry 2005; 66: 870–86PubMedCrossRef
123.
Gentile S. Prophylactic treatment of bipolar disorder in pregnancy and breastfeeding: focus on emerging mood stabilizers. Bipol Disord 2006; 8(3): 207–20CrossRef
Metadaten
Titel
Atypical Antipsychotics for the Treatment of Bipolar Disorder
More Shadows than Lights
verfasst von
Dr Salvatore Gentile
Publikationsdatum
01.05.2007
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 5/2007
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200721050-00002

Weitere Artikel der Ausgabe 5/2007

CNS Drugs 5/2007 Zur Ausgabe

Adis Drug Profile

Pramipexole

Adis Drug Profile

Paliperidone Extended Release

Review Article

Use of Non-Benzodiazepine Hypnotics in the Elderly

Adis Drug Profiles

Paliperidone Extended Release

Original Research Article

Effect of Adjunctive Modafinil on Wakefulness and Quality of Life in Patients with Excessive Sleepiness-Associated Obstructive Sleep Apnoea/Hypopnoea Syndrome

Adis Drug Profiles

Paliperidone Extended Release

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise